Emerging biologic therapies for systemic lupus erythematosus.

IF 5.2 2区医学 Q1 RHEUMATOLOGY

Current opinion in rheumatology Pub Date : 2024-05-01 Epub Date: 2024-02-01 DOI:10.1097/BOR.0000000000001003

Hiroshi Kato, J Michelle Kahlenberg

{"title":"Emerging biologic therapies for systemic lupus erythematosus.","authors":"Hiroshi Kato, J Michelle Kahlenberg","doi":"10.1097/BOR.0000000000001003","DOIUrl":null,"url":null,"abstract":"Purpose of review: The approval of belimumab and anifrolumab has expanded the scope of treatment for systemic lupus erythematosus (SLE) patients. However, many patients remain refractory to currently available therapies and suffer from drug toxicities. This review will discuss approved and target-specific therapeutics in development that bring hope for better SLE treatments.Recent findings: Since the last review on this subject in the journal, the FDA has approved anifrolumab and belimumab for SLE and lupus nephritis (LN), respectively. A fully humanized anti-CD20, obinutuzumab, met the primary end point in a phase II trial in LN. A Tyk2 inhibitor, deucravacitinib, and an antibody targeting plasmacytoid dendritic cells, litifilimab, met the primary end point in phase II trials in SLE and cutaneous lupus erythematosus (CLE). Ustekinumab and baricitinib met the primary end point in phase II but not in phase III trials.Summary: While many drug candidates which met the end points in phase II trials have failed phase III trials, the number of target-specific therapies for SLE has continued to expand.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"169-175"},"PeriodicalIF":5.2000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BOR.0000000000001003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The approval of belimumab and anifrolumab has expanded the scope of treatment for systemic lupus erythematosus (SLE) patients. However, many patients remain refractory to currently available therapies and suffer from drug toxicities. This review will discuss approved and target-specific therapeutics in development that bring hope for better SLE treatments.

Recent findings: Since the last review on this subject in the journal, the FDA has approved anifrolumab and belimumab for SLE and lupus nephritis (LN), respectively. A fully humanized anti-CD20, obinutuzumab, met the primary end point in a phase II trial in LN. A Tyk2 inhibitor, deucravacitinib, and an antibody targeting plasmacytoid dendritic cells, litifilimab, met the primary end point in phase II trials in SLE and cutaneous lupus erythematosus (CLE). Ustekinumab and baricitinib met the primary end point in phase II but not in phase III trials.

Summary: While many drug candidates which met the end points in phase II trials have failed phase III trials, the number of target-specific therapies for SLE has continued to expand.

查看原文本刊更多论文

治疗系统性红斑狼疮的新兴生物疗法。

审查目的：贝利木单抗（belimumab）和阿尼单抗（anifrolumab）的批准扩大了系统性红斑狼疮（SLE）患者的治疗范围。然而，许多患者对目前可用的疗法仍不耐受，并遭受药物毒性的折磨。本综述将讨论已获批准和正在开发中的靶向治疗药物，它们为更好地治疗系统性红斑狼疮带来了希望：最近的发现：自本刊上一篇相关综述发表以来，美国食品和药物管理局（FDA）已批准阿尼单抗（anifrolumab）和贝利木单抗（belimumab）分别用于系统性红斑狼疮和狼疮肾炎（LN）。一种全人源化的抗CD20药物obinutuzumab在狼疮肾炎的II期试验中达到了主要终点。一种Tyk2抑制剂deucravacitinib和一种靶向浆细胞树突状细胞的抗体litifilimab在系统性红斑狼疮和皮肤红斑狼疮（CLE）的II期试验中达到了主要终点。总结：虽然许多在II期试验中达到终点的候选药物在III期试验中失败了，但治疗系统性红斑狼疮的靶向特异性疗法的数量仍在继续增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in rheumatology 医学-风湿病学

CiteScore

9.70

自引率

2.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A high impact review journal which boasts an international readership, Current Opinion in Rheumatology offers a broad-based perspective on the most recent and exciting developments within the field of rheumatology. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include vasculitis syndromes, medical physiology and rheumatic diseases, crystal deposition diseases and rheumatoid arthritis. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.